Exclusive Technology Seen As Breakthrough to Further Increase Bioavailability
SEATTLE, WA, September 3, 2013 - (ACCESSWIRE) - Plandai Biotechnology, Inc. (PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutriceutical, and pharmaceutical, today announced that it has signed an exclusive agreement with North-West University in Potchefstroom, South Africa, that holds the patents and associated intellectual property associated with the entrapment of compounds in long-chain fatty acids-based nano- and micro-particles, known as Pheroid(R). Under the terms of the world license, Plandai has the exclusive right to use the Pheroid(R) technology with all Phytofare polyene-based extracts, which includes proprietary extracts of most botanical matter, for human and animal use.
The Pheroid(R) technology, developed for a number of applications by Professors Anne Grobler Awie Kotze and Jeanetta du Plessis of North-West University, allows particles to be encapsulated, or entrapped, in different media that can improve absorption through protecting the contents. It is actively used worldwide for industrial and agricultural purposes and has been extensively tested in humans and animals by Professor Grobler where it has shown an ability to significantly increase the level of absorption of the entrapped particles into the bloodstream.
For Plandai's purposes, the technology will enable the company to produce Phytofare topical products with significantly enhanced tissue absorption and oral products that can help Phytofare survive intact on its passage through the digestive tract and into the bloodstream. Once in the bloodstream, human cells perceive the Pheroid(R) material as a biological building block and as a source of energy, allowing them to pass through the cell membrane and, by metabolism of the long chain fatty acids, release the valuable phytonutrients directly to the tissues.
Roger Duffield, chairman and chief executive officer of Plandai Biotechnology, commented, "This agreement gives us the final piece of the equation to provide a reliable way to deliver Phytofare products in the most efficient and bioavailable form. Botanical extracts, including catechins, carotenoids, and citrus bioflavonoids and limonoids, have always generated amazing laboratory results. But poor bioavailability and gut metabolization of the molecules have prevented these results from being replicated in human trials. We believe that the Pheroid(R) nano-entrapment system will help us deliver our already highly-bioavailable Phytofare products in a pure and unchanged state to the target site."
Under the terms of the agreement, Plandai can develop, test, and then manufacture Phytofare Pheroid ("ph^2TM") products from different botanical extracts for human and animal use. The first Phytofare product to be entrapped in Pheroid and marketed as an ingredient will be Phytofare Catechin Complex, which is a highly bioavailable extract produced from green tea catechins. The license calls for a 2% annual royalty on net sales of Plandai products that incorporate the Pheroid(R) technology and is exempt for Plandai humanitarian products.
About PlandaiBiotechnology, Inc.
Plandai Biotechnology, Inc. and its subsidiaries develop highly bioavailable, phytonutrient rich extracts which are being utilized to deliver a new family of drugs to safely and affordably use in a multitude of diseases and conditions. Plandai Biotechnology controls every aspect of the process, from growing the raw materials on its farms in South Africa, to producing its patented Phytofare extracts in-house, allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process. Targeted industries for the Company's products include beverage, cosmeceutical, wellness, nutraceutical, anti-aging, and pharmaceutical. For more information, please visit http://www.plandaibiotech.com.
Safe Harbor Statement
The information provided may contain forward-looking statements and involve risks and uncertainties. Results, events and performances could vary from those contemplated. These statements involve risks and uncertainties which may cause actual results, expressed or implied, to differ from predicted outcomes. Risks and uncertainties include product demand, market competition, and Planda's ability to meet current or future plans. Investors should study and understand all risks before making an investment decision. Readers are recommended not to place undue reliance on forward-looking statements or information. Planda is not obliged to publicly release revisions to any forward-looking statement, to reflect events or circumstances afterward, or to disclose unanticipated occurrences, except as required under applicable laws.
SOURCE: Plandai Biotechnology, Inc.
- Health Care Industry